NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT05658601

CompletedN/A

Sponsor: Bristol-Myers Squibb

Conditions: Multiple Sclerosis, Relapsing-Remitting

Countries: Italy

The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with RRMS according to 2017 revised McDonald criteria
* Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment
* Patient with a MRI performed within three months before the enrollment
* Patient eligible to ozanimod according to SmPC

Exclusion Criteria:

* Patients with clinical forms of MS other than RRMS
* Patients unable to participate for various reasons
* Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective
* Contraindications to ozanimod according to SmPC

Other protocol-defined Inclusion/Exclusion Criteria apply.

Locations (1)

Isernia, Italy